(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
Live Chart Being Loaded With Signals
EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally...
Stats | |
---|---|
今日成交量 | 137 154 |
平均成交量 | 313 756 |
市值 | 134.76M |
EPS | £0 ( 2024-03-25 ) |
Last Dividend | £1.200 ( 2022-11-02 ) |
Next Dividend | £0 ( N/A ) |
P/E | 29.70 |
ATR14 | £0.767 (2.57%) |
EKF Diagnostics Holdings 相关性
10 最正相关 | |
---|---|
MPL.L | 0.932 |
PDL.L | 0.924 |
TPX.L | 0.923 |
OMIP.L | 0.916 |
RDT.L | 0.913 |
SCLP.L | 0.913 |
3SNV.L | 0.909 |
TBLD.L | 0.909 |
3SUB.L | 0.906 |
DSW.L | 0.902 |
10 最负相关 | |
---|---|
AEXG.L | -0.959 |
EMR.L | -0.958 |
CFX.L | -0.957 |
INSE.L | -0.949 |
SPEC.L | -0.939 |
VAST.L | -0.939 |
SKL.L | -0.938 |
NWT.L | -0.934 |
IPF.L | -0.932 |
GRA.L | -0.926 |
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
EKF Diagnostics Holdings 财务报表
Annual | 2023 |
营收: | £52.61M |
毛利润: | £24.44M (46.45 %) |
EPS: | £0.00520 |
FY | 2023 |
营收: | £52.61M |
毛利润: | £24.44M (46.45 %) |
EPS: | £0.00520 |
FY | 2022 |
营收: | £66.64M |
毛利润: | £24.04M (36.07 %) |
EPS: | £-0.0209 |
FY | 2021 |
营收: | £81.84M |
毛利润: | £39.37M (48.10 %) |
EPS: | £0.0347 |
Financial Reports:
No articles found.
EKF Diagnostics Holdings Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£0 (N/A) |
£1.200 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | £1.000 | 2020-11-04 |
Last Dividend | £1.200 | 2022-11-02 |
Next Dividend | £0 | N/A |
Payout Date | 2022-12-01 | |
Next Payout Date | N/A | |
# dividends | 4 | -- |
Total Paid Out | £3.30 | -- |
Avg. Dividend % Per Year | 0.73% | -- |
Score | 3.09 | -- |
Div. Sustainability Score | 9.77 | |
Div.Growth Potential Score | 5.27 | |
Div. Directional Score | 7.52 | -- |
Year | Amount | Yield |
---|---|---|
2020 | £1.000 | 2.98% |
2021 | £1.100 | 1.62% |
2022 | £1.200 | 1.58% |
2023 | £0 | 0.00% |
2024 | £0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TYMN.L | Dividend Knight | 2023-08-03 | Annually | 29 | 2.69% | |
MGCI.L | Dividend King | 2023-08-03 | Quarterly | 6 | 3.54% | |
CTEC.L | Dividend Knight | 2023-08-17 | Semi-Annually | 8 | 1.46% | |
SCP.L | Dividend Knight | 2023-07-13 | Semi-Annually | 31 | 1.83% | |
HTG.L | Dividend King | 2023-10-05 | Semi-Annually | 32 | 1.82% | |
BCPT.L | Dividend King | 2023-09-14 | Monthly | 20 | 2.80% | |
WKP.L | Dividend Junior | 2023-07-06 | Annually | 31 | 2.53% | |
NAIT.L | Dividend Knight | 2023-07-20 | Quarterly | 53 | 2.33% | |
ECK.L | Dividend Knight | 2023-09-21 | Annually | 14 | 0.93% | |
SOM.L | Dividend King | 2023-09-21 | Semi-Annually | 18 | 5.37% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0447 | 1.500 | 9.11 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0291 | 1.200 | 9.03 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0358 | 1.500 | -0.713 | -1.070 | [0.1 - 1] |
payoutRatioTTM | 2.32 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 2.69 | 0.800 | 1.545 | 1.236 | [1 - 3] |
quickRatioTTM | 1.768 | 0.800 | 4.31 | 3.45 | [0.8 - 2.5] |
cashRatioTTM | 0.814 | 1.500 | 6.59 | 9.89 | [0.2 - 2] |
debtRatioTTM | 0.0507 | -1.500 | 9.16 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 63.41 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.0139 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -0.00146 | 2.00 | -0.000732 | -0.00146 | [0 - 20] |
debtEquityRatioTTM | 0.0611 | -1.500 | 9.76 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.464 | 1.000 | 5.59 | 5.59 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0904 | 1.000 | -0.192 | -0.192 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 1.540 | 1.000 | 2.56 | 2.56 | [0.2 - 2] |
assetTurnoverTTM | 0.651 | 0.800 | 9.00 | 7.20 | [0.5 - 2] |
Total Score | 9.77 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 57.30 | 1.000 | 4.31 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0358 | 2.50 | -0.458 | -1.070 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.00146 | 2.00 | -0.000488 | -0.00146 | [0 - 30] |
dividendYielPercentageTTM | 4.04 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.0139 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 2.32 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 57.30 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.120 | 1.000 | 9.50 | 0 | [0.1 - 0.5] |
Total Score | 5.27 |
EKF Diagnostics Holdings
EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; DiaSpect Hemoglobin T analyzer; Hemo Control, a hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers' milk; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company provides clinical chemical analyzers, such as Beta-hydroxybutyrate for monitoring ketosis; Glycated Albumin; Glycated Serum Protein; Nitro-tab Ketone tablets; and Procalcitonin marker for bacterial infection and sepsis, as well as reagents, calibrators, standards, and controls. Additionally, it offers RaPET Serology immunoassay kits; QuStick Strep A for Strep A infection treatment; Altair 240, a chemistry analyzer; Excel, a semi-automated chemistry analyzer; Micro 12, a micro centrifuge for clinical, molecular, and bacteriological applications; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; Uri-Trak 120 urine analyzer; and kits and other services related to COVID-19, as well as contract manufacturing solutions to third-party businesses and laboratory services. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。